<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Hematological VitroScreen

Patient primary never-passaged Hematological models for screening.

Industry-leading Hematologic Model Screening

Champions' Hematological VitroScreens offer a quick, cost-effective solution to test your therapeutics in an ex vivo hematologic assay evaluating efficacy and mechanisms of action in primary patient samples.

  • Largest primary hematological repository of Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM) models
  • Well-characterized models featuring patient responses, clinical annotation, NGS data (WES and RNASeq), deep phenotyping using flow cytometry, proteomics, and phospho-proteomics datasets available in Lumin

Data-Driven Insights to Accelerate Your Hematologic Program

All models are hand-picked for each VitroScreen and have been characterized for ex vivo cell viability and several standard of care drug dose responses, available in Lumin.
Our standard endpoint is a cell viability assessment by CellTiter-Glo®, and additional optional endpoints are available during each VitroScreen enrollment period to maximize the insight our partners can derive from each experiment. 
VitroScreen results in AML and B-ALL models in response to Standards of Care.

Hematological VitroScreen Endpoints


Western Blot


The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology (IO) drugs in only 4 days using primary patient models.


Tab Imges_Medium21